RBC Capital Markets reiterated their outperform rating on shares of Concordia Healthcare Corp. (NASDAQ:CXRX) in a research report sent to investors on Wednesday morning. RBC Capital Markets currently has a $18.50 target price on the stock.

CXRX has been the topic of several other reports. TD Securities cut Concordia Healthcare Corp. from a buy rating to a hold rating in a research note on Thursday, August 4th. GMP Securities cut Concordia Healthcare Corp. from a buy rating to a hold rating in a research note on Monday, August 15th. Goldman Sachs Group Inc. reduced their price target on Concordia Healthcare Corp. from $26.00 to $13.00 and set a neutral rating on the stock in a research note on Monday, August 15th. Canaccord Genuity cut Concordia Healthcare Corp. to a buy rating and set a $10.00 price target on the stock. in a research note on Friday, September 16th. Finally, Royal Bank Of Canada reaffirmed an outperform rating and issued a $73.00 price target on shares of Concordia Healthcare Corp. in a research note on Tuesday, June 21st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the stock. Concordia Healthcare Corp. has a consensus rating of Hold and an average target price of $32.41.

Shares of Concordia Healthcare Corp. (NASDAQ:CXRX) traded down 4.18% during midday trading on Wednesday, hitting $4.13. The stock had a trading volume of 194,635 shares. The stock’s market cap is $210.70 million. The stock’s 50-day moving average is $6.25 and its 200-day moving average is $18.74. Concordia Healthcare Corp. has a 12 month low of $4.11 and a 12 month high of $44.00.

Concordia Healthcare Corp. (NASDAQ:CXRX) last posted its earnings results on Friday, August 12th. The company reported $1.38 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.38. Concordia Healthcare Corp. had a positive return on equity of 25.18% and a negative net margin of 81.80%. The firm had revenue of $231.70 million for the quarter, compared to analysts’ expectations of $229.76 million. Concordia Healthcare Corp.’s revenue for the quarter was up 208.1% compared to the same quarter last year. Equities analysts anticipate that Concordia Healthcare Corp. will post $5.15 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the company. PCJ Investment Counsel Ltd. boosted its stake in Concordia Healthcare Corp. by 14.0% in the first quarter. PCJ Investment Counsel Ltd. now owns 676,390 shares of the company’s stock valued at $17,382,000 after buying an additional 83,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Concordia Healthcare Corp. by 15.5% in the first quarter. Goldman Sachs Group Inc. now owns 79,981 shares of the company’s stock valued at $2,047,000 after buying an additional 10,734 shares in the last quarter. Geode Capital Management LLC boosted its stake in Concordia Healthcare Corp. by 12.4% in the first quarter. Geode Capital Management LLC now owns 20,553 shares of the company’s stock valued at $526,000 after buying an additional 2,270 shares in the last quarter. Legal & General Group Plc boosted its stake in Concordia Healthcare Corp. by 91.2% in the first quarter. Legal & General Group Plc now owns 4,403 shares of the company’s stock valued at $113,000 after buying an additional 2,100 shares in the last quarter. Finally, HRS Investment Holdings LLC boosted its stake in Concordia Healthcare Corp. by 100.0% in the first quarter. HRS Investment Holdings LLC now owns 15,400 shares of the company’s stock valued at $394,000 after buying an additional 7,700 shares in the last quarter. Hedge funds and other institutional investors own 33.93% of the company’s stock.

About Concordia Healthcare Corp.

5 Day Chart for NASDAQ:CXRX

Receive News & Stock Ratings for Concordia Healthcare Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp. and related stocks with our FREE daily email newsletter.